相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain
Antonio Olry de Labry Lima et al.
BREAST (2021)
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PARP inhibitors: a tsunami of indications in different malignancies
Gaelle Haddad et al.
PHARMACOGENOMICS (2020)
Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy
Hope S. Rugo et al.
JNCI CANCER SPECTRUM (2020)
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
Holly Guy et al.
PHARMACOECONOMICS (2019)
Trajectories of Injectable Cancer Drug Costs After Launch in the United States
Noa Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany
Albrecht Waschke et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
J. Ettl et al.
ANNALS OF ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
Lixian Zhong et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries
Sabine Vogler et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2017)
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
H. Mamiya et al.
ANNALS OF ONCOLOGY (2017)
Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Ben Y. Durkee et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review
Noman Paracha et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2016)
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: A cost-effectiveness analysis
Haller J. Smith et al.
GYNECOLOGIC ONCOLOGY (2015)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Market Spiral Pricing of Cancer Drugs
Donald W. Light et al.
CANCER (2013)
Economic burden of cancer across the European Union: a population-based cost analysis
Ramon Luengo-Fernandez et al.
LANCET ONCOLOGY (2013)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Overview of Parametric Survival Analysis for Health-Economic Applications
K. Jack Ishak et al.
PHARMACOECONOMICS (2013)
Subgroup Economic Analysis for Glioblastoma in a Health Resource-Limited Setting
Bin Wu et al.
PLOS ONE (2012)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Health-state utility values in breast cancer
Tessa Peasgood et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer
B. Sherrill et al.
BRITISH JOURNAL OF CANCER (2008)
分享论文
